[A20-25] Fidaxomicin (Clostridioides difficile infection) - Benefit assessment according to §35a Social Code Book V

Last updated 15.06.2020

Project no.:

Commission awarded on 11.03.2020 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Commission completed

Drug Assessment

Application field:
Immune system and infections


Children and adolescents with Clostridioides difficile infection

Result of dossier assessment:

Mild course of disease: added benefit not proven for girls; hint of lesser benefit for boys. Severe and/or recurrent course of disease: hint of considerable added benefit.


After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.


Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.


Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form